EBITDA CAGR uses clean operating EBITDA derived from reported operating income plus depreciation and amortization.
Over longer horizons, EBITDA CAGR averages 64.49% over 3 years and 14.65% over 5 years; the trailing 12 months came in at +33.22%. EBITDA CAGR shows how the company's operating profitability has grown before depreciation and amortization. This reflects the growth of the core business's cash-operating earnings power, independent of capital-intensity and accounting depreciation choices.
AMRX EBITDA CAGR Chart
Amneal Pharmaceuticals, Inc. (AMRX)
tgmcharts.com
AMRX Quarterly EBITDA Growth (YoY)
EBITDA growth vs the same fiscal quarter in the prior fiscal year, last 27 comparable quarters.
tgmcharts.com
EBITDA
AMRX Quarterly EBITDA
$193.78M
Reported quarterly EBITDA; no daily interpolation. Q2 FY2026 (2026-06-30): $193.78M.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A Quote observation: 2026-10-06T19:45:45.724Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
tgmcharts.com
AMRX EBITDA CAGR History
Year
Start EBITDA
End EBITDA
Change
% Change
2025
$485.52M
$646.66M
+$161.15M
+33.19%
2024
$433.77M
$485.52M
+$51.74M
+11.93%
2023
$145.25M
$433.77M
+$288.53M
+198.65%
2022
$386.12M
$145.25M
−$240.88M
-62.38%
2021
$326.54M
$386.12M
+$59.58M
+18.25%
2020
$117.73M
$326.54M
+$208.81M
+177.37%
2018
$291.04M
$117.73M
−$173.31M
-59.55%
2017
$317.90M
$291.04M
−$26.86M
-8.45%
2016
$252.68M
$317.90M
+$65.22M
+25.81%
2015
$243.28M
$252.68M
+$9.39M
+3.86%
Quarterly EBITDA: QoQ & YoY
Period
Period End
Value
QoQ Growth
YoY Growth
Q2 FY2026
2026-06-30
$193.78M
+4.1%
+13.0%
Q1 FY2026
2026-03-31
$186.06M
+13.6%
+15.9%
Q4 FY2025
2025-12-31
$163.73M
+203.4%
+15.4%
Q3 FY2025
2025-09-30
$53.96M
-68.5%
-63.5%
Q2 FY2025
2025-06-30
$171.49M
+6.8%
+13.5%
Q1 FY2025
2025-03-31
$160.51M
+13.1%
+258.4%
Q4 FY2024
2024-12-31
$141.92M
-4.0%
+99.5%
Q3 FY2024
2024-09-30
$147.77M
-2.2%
+11.2%
Q2 FY2024
2024-06-30
$151.04M
+237.3%
+10.1%
Q1 FY2024
2024-03-31
$44.78M
-37.0%
-51.6%
Q4 FY2023
2023-12-31
$71.13M
-46.5%
-26.7%
Q3 FY2023
2023-09-30
$132.85M
-3.2%
+25.4%
Q2 FY2023
2023-06-30
$137.19M
+48.2%
N/A
Q1 FY2023
2023-03-31
$92.60M
-4.6%
+14.2%
Q4 FY2022
2022-12-31
$97.09M
-8.4%
+34.2%
Q3 FY2022
2022-09-30
$105.96M
N/A
+19.5%
QoQ Growth compares the previous fiscal quarter; YoY Growth compares the same fiscal quarter in the prior fiscal year. Missing or ambiguous fiscal periods render N/A.
